Literature DB >> 16938665

Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia.

Pei Lin1, Dan Jones, L Jeffrey Medeiros, Weina Chen, Francisco Vega-Vazquez, Rajyalakshmi Luthra.   

Abstract

FLT3 gene mutations, either internal tandem duplication (ITD) or D835 point mutations, have been studied extensively in acute myeloid leukemia and myelodysplastic syndrome (MDS). Little is known about FLT3 mutations in chronic myeloproliferative diseases (CMPDs) or their relationship with V617F JAK2 mutations. We analyzed bone marrow samples from 142 patients with Philadelphia (Ph) chromosome- CMPD or CMPD/MDS and from 119 patients with Ph+ chronic myeloid leukemia (CML) using a multiplex polymerase chain reaction assay. FLT3 mutations, 11 ITD and 2 D835, were detected in 13 (9.2%) patients with CMPD or CMPD/MDS, 7 in blast phase and 6 in chronic phase. Analyses for JAK2 mutations in 11 of 13 cases were all negative. By contrast, no FLT3 mutations were detected in CML, including 108 chronic and 11 blast phase cases. FLT3 mutations occur in approximately 10% of CMPD and CMPD/MDS but are not observed in JAK2+ CMPD or in CML.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16938665     DOI: 10.1309/JT5BE2L1FGG8P8Y6

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  28 in total

1.  Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia.

Authors:  Aziz Nazha; Jorge Cortes; Stefan Faderl; Sherry Pierce; Naval Daver; Tapan Kadia; Gautam Borthakur; Raja Luthra; Hagop Kantarjian; Farhad Ravandi
Journal:  Haematologica       Date:  2012-04-24       Impact factor: 9.941

2.  Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.

Authors:  Aref Al-Kali; Jorge Cortes; Stefan Faderl; Dan Jones; Caroline Abril; Sherry Pierce; Mark Brandt; Hagop Kantarjian; Farhad Ravandi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-08

3.  Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.

Authors:  Talha Badar; Hagop M Kantarjian; Graciela M Nogueras-Gonzalez; Gautam Borthakur; Guillermo Garcia Manero; Michael Andreeff; Marina Konopleva; Tapan M Kadia; Naval Daver; William G Wierda; Raja Luthra; Keyur Patel; Betul Oran; Richard Champlin; Farhad Ravandi; Jorge E Cortes
Journal:  Am J Hematol       Date:  2015-09-10       Impact factor: 10.047

4.  TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation.

Authors:  Keyur P Patel; Faisal A Khokhar; Tariq Muzzafar; M James You; Carlos E Bueso-Ramos; Farhad Ravandi; Sherrie Pierce; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2012-08-31       Impact factor: 7.842

5.  Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias.

Authors:  Dan Jones; Hui Yao; Angela Romans; Caroline Dando; Sherry Pierce; Gautam Borthakur; Amy Hamilton; Carlos Bueso-Ramos; Farhad Ravandi; Guillermo Garcia-Manero; Hagop Kantarjian
Journal:  Genes Chromosomes Cancer       Date:  2010-02       Impact factor: 5.006

6.  Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.

Authors:  Koichi Takahashi; Hagop Kantarjian; Naveen Pemmaraju; Michael Andreeff; Gautam Borthakur; Stefan Faderl; Guillermo Garcia-Manero; Sherry Pierce; Rajyalakshmi Luthra; Marylou Cardenas-Turanzas; Zeev Estrov; Farhad Ravandi; Jorge Cortes
Journal:  Br J Haematol       Date:  2013-03-27       Impact factor: 6.998

7.  CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Wenli Zheng; L Jeffrey Medeiros; Ying Hu; Linda Powers; Jorge E Cortes; Farhad Ravandi-Kashani; Hagop H Kantarjian; Sa A Wang
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-01-10

8.  Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.

Authors:  Farhad Ravandi; Hagop Kantarjian; Stefan Faderl; Guillermo Garcia-Manero; Susan O'Brien; Charles Koller; Sherry Pierce; Mark Brandt; Deborah Kennedy; Jorge Cortes; Miloslav Beran
Journal:  Leuk Res       Date:  2009-10-29       Impact factor: 3.156

Review 9.  Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.

Authors:  Katerina Zoi; Nicholas C P Cross
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

10.  Fms-like tyrosine kinase (FLT) 3 and FLT3 internal tandem duplication in different types of adult leukemia: analysis of 147 patients.

Authors:  Hong-Ling Peng; Guang-Sen Zhang; Fan-Jie Gong; Jian-Kai Shen; Yang Zhang; Yun-Xiao Xu; Wen-Li Zheng; Chong-Wen Dai; Min-Fei Pei; Jun-Jie Yang
Journal:  Croat Med J       Date:  2008-10       Impact factor: 1.351

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.